^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunostimulant

    Related drugs:
    1d
    Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy (clinicaltrials.gov)
    P2, N=33, Terminated, Medical University of South Carolina | Completed --> Terminated; Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.
    Trial termination
    |
    ProstVac (rilimogene galvacirepvec)
    1d
    A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults. (clinicaltrials.gov)
    P1/2, N=368, Not yet recruiting, SK Bioscience Co., Ltd.
    New P1/2 trial
    |
    IL4 (Interleukin 4)
    1d
    INTerpath-13: A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) (clinicaltrials.gov)
    P2, N=180, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • intismeran autogene (mRNA-4157)
    1d
    Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons (clinicaltrials.gov)
    P2, N=170, Recruiting, Johns Hopkins University | Not yet recruiting --> Recruiting
    Enrollment open
    2d
    Advancing glioblastoma immunotherapy: Molecular pathways and innovative therapeutic strategies. (PubMed, Pathol Res Pract)
    Vaccines such as DCVax-L and oncolytic viruses including G47Δ have demonstrated promising outcomes in the clinical studies...The future research can focus on highlighting the complicated connections between the immune system and GBM, utilizing perspectives from preclinical models and clinical studies to formulate more effective and customized treatment options. This review emphasizes on the recent research results and clinical data, providing insights into prospective developments in GBM immunotherapy and highlighting the necessity of a comprehensive strategy to enhance patient outcomes.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2)
    |
    DCVax-L (autologous dendritic cell vaccine leaded with autologous tumor cell lysate)
    3d
    IMUNO-RZV: Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators (clinicaltrials.gov)
    P4, N=200, Not yet recruiting, University of Sao Paulo General Hospital
    New P4 trial
    3d
    Study of GC101 TIL in Brain Glioma (Soochow2) (clinicaltrials.gov)
    P1, N=50, Recruiting, Shanghai Juncell Therapeutics | Trial completion date: May 2025 --> May 2027 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • GC101 TIL
    3d
    Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older (clinicaltrials.gov)
    P1/2, N=1530, Active, not recruiting, Sanofi Pasteur, a Sanofi Company | Trial completion date: Sep 2027 --> Jan 2027 | Trial primary completion date: Jul 2027 --> Jan 2027
    Trial completion date • Trial primary completion date
    3d
    MIZAR-002: A Phase 1b Study of GC101 TIL in Advanced Melanoma (clinicaltrials.gov)
    P1/2, N=18, Completed, Shanghai Juncell Therapeutics | Recruiting --> Completed | Trial completion date: Jul 2025 --> Nov 2025
    Trial completion • Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    GC101 TIL
    3d
    KUNLUN-001: A Study of GC203 TIL in Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=18, Recruiting, Shanghai Juncell Therapeutics | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial primary completion date
    4d
    A Study of GC203 TIL in Advanced Gynecologic Tumors (10hospital) (clinicaltrials.gov)
    P1, N=26, Completed, Shanghai Juncell Therapeutics | Recruiting --> Completed | N=50 --> 26
    Trial completion • Enrollment change
    |
    cyclophosphamide
    4d
    A Study of GC101 TIL in Advanced Breast Cancer (10hospital) (clinicaltrials.gov)
    P1, N=50, Recruiting, Shanghai Juncell Therapeutics | Trial primary completion date: Dec 2024 --> Dec 2026 | Trial completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • GC101 TIL